Hot Stocks
|
Can-Fite… Can-Fite BioPharmannounced that Dr. Rifaat Safadi, Principal Investigator of the Company's Phase II study of Namodenoson in the treatment of NAFLD/NASH delivered a late-breaking oral presentation at the AASLD conference, The Liver Meeting Digital Experience 2020. Titled "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study Of The Efficacy And Safety Of Namodenoson , An A3 Adenosine Receptor (Agonist, In Treating Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis " the oral presentation was given on Sunday, November 15 by Dr. Safadi, Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center, Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hebrew University in Israel. Titled "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study Of The Efficacy And Safety Of Namodenoson (CF102), An A3 Adenosine Receptor (A3AR) Agonist, In Treating Non-Alcoholic Fatty Liver Disease (NAFLD) And Non-Alcoholic Steatohepatitis (NASH)" the oral presentation was given on Sunday, November 15 by Dr. Safadi, Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center, Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hebrew University in Israel. ShowHide Related Items >><< - 10/06/20
- IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat
- 08/31/20
- Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study
- 08/25/20
- Can-Fite BioPharma granted patent from EPO for Namodenoson
- 07/27/20
- Can-Fite BioPharma submits IND application for Phase 2 Piclidenoson study to FDA
|
Conference/Events
|
AASLD 2020: The Virtual… AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link ShowHide Related Items >><< - 11/13/20
- Halozyme: CHMP recommends EU approval of Roche's Phesgo
- 10/29/20
- Roche receives FDA approval for cobas EGFR Mutation Test v2
- 10/22/20
- Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527
- 10/21/20
- PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA
- 11/11/20
- Novocure receives CE Mark for NovoTTF-100L system
- 10/29/20
- Novocure forms alliance with NYU Grossman School of Medicine
- 08/13/20
- Novocure announces Wilco Groenhuysen as COO, other leadership promotions
- 07/22/20
- Novocure enrolls first patient in EF-33 Phase 2 pilot trial
- 11/04/20
- Match Group says future remains 'challenging to predict'
- 09/28/20
- Match Group appoints Tracey Breeden as Head of Safety and Social Advocacy
- 09/03/20
- Match Group says DOJ closes investigation
- 08/17/20
- Soros boosts stakes in Alphabet, T-Mobile, takes position in Alibaba
- 11/15/20
- Agilent receives expanded FDA approval for PD-L1 IHC 22C3 pharmDx
- 11/13/20
- FDA approves Merck's Keytruda in combination with chemo in TNBC
- 11/13/20
- Surface announces SRF617, SRF388 to advance to combination, expansion stages
- 11/11/20
- Xoma earns $1M milestone payment from 2018 royalty purchase agreement
- 11/10/20
- Mallinckrodt initiates NOTICE study for use of INOmax gas in COVID-19 patients
- 10/21/20
- DOJ announces settlement agreement of over $8B with opioid maker Purdue Pharma
- 10/12/20
- Mallinckrodt voluntarily initiates Chapter 11 proceedings in bankruptcy court
- 10/12/20
- Mallinckrodt voluntarily initiates Chapter 11 proceedings
MDGL Madrigal Pharmaceuticals - 11/13/20
- Madrigal discloses data from MAESTRO-NAFLD trial ahead of AASLD presentation
- 10/01/20
- Madrigal announces acceptance of three abstracts for The Liver Meeting
- 09/03/20
- Madrigal exceeds target enrollment in Phase 3 MAESTRO NAFLD-1 trial
- 06/29/20
- Intercept plunges, drags down some NASH peers after CRL from FDA
- 11/10/20
- Inventiva announces conclusions from phase II meeting with FDA
- 11/06/20
- Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed
- 11/02/20
- Inventiva announces publication on role of PPARs in NASH treatment
- 10/19/20
- Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil
- 11/09/20
- GSK's ViiV says injectable cabotegravir superior to oral SOC for HIV prevention
- 11/02/20
- Horizon Therapeutics names Karin Rosen, M.D., Ph.D. as Chief Scientific Officer
- 10/28/20
- Sanofi, GSK to support COVAX with 200M doses of COVID-19 vaccine
- 10/26/20
- AnaptysBio, GlaxoSmithKline amend strategic immuno-oncology collaboration
- 10/27/20
- Exelixis announces Takeda, Ono submit application for Cabometyx in Japan
- 10/26/20
- Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo
- 10/19/20
- Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo
- 10/09/20
- Exelixis, Aurigene disclose new AUR102 data at ENA Symposium
- 11/10/20
- Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint
- 11/09/20
- Eisai presents latest BAN2401 data at CTAD
- 11/06/20
- Eisai down 19% as FDA panel votes on Alzheimer's drug candidate
- 10/30/20
- Biogen announces EMA acceptance of MAA for aducanumab
- 11/13/20
- Durect reports new safety data and efficacy signals from Phase 1b NASH trial
- 11/02/20
- Durect names Dr. Norman Sussman as Chief Medical Officer
- 10/05/20
- Durect to present results from 4-week Phase 1b clinical study of DUR-928
- 09/23/20
- Durect doses first patient in Phase 2 DUR-928 study of COVID-19 patients
- 11/05/20
- CymaBay announces study to evaluate potential of GPR119 agonists
- 08/27/20
- CymaBay presents final results from 52-week Phase 2 study in PBC
- 08/20/20
- CymaBay announces presentations during Digital International Liver Conference
- 08/03/20
- CymaBay announces topline results from ENHANCE for seladelpar
- 10/06/20
- IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat
- 08/31/20
- Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study
- 08/25/20
- Can-Fite BioPharma granted patent from EPO for Namodenoson
- 07/27/20
- Can-Fite BioPharma submits IND application for Phase 2 Piclidenoson study to FDA
- 11/12/20
- Bristol-Myers presents outcomes in 'hard to treat' blood cancers at ASH
- 11/09/20
- Stryker appoints Giovanni Caforio to board of directors
- 11/09/20
- Kitov expands planned Phase 1/2 clinical trial of CM24
- 11/09/20
- Bristol-Myers: Phase 2 study evaluating deucravacitinib met primary endpoint
- 11/13/20
- AstraZeneca announces data from U.S. hospitalized heart failure registry
- 11/13/20
- Ionis, AstraZeneca report efficacy and safety results of antisense medicine
- 11/12/20
- AstraZeneca says Phase 2 Calquence COVID-19 trials didn't meet primary endpoint
- 11/10/20
- AstraZeneca, Amgen study for severe asthma meets primary endpoint
- 11/13/20
- Albireo Pharma unveils novel bile acid modulators for adult liver diseases
- 11/13/20
- Albireo Pharma announces PEDFIC 1 meets primary, secondary endpoints
- 09/08/20
- Albireo Pharma jumps 64% after PEDFIC 1 Phase 3 trial met endpoints
- 09/08/20
- Albireo Pharma: PEDFIC 1 Phase 3 trial met two primary endpoints
- 09/10/20 Cowen
- Albireo Pharma price target raised to $65 from $39 at Cowen
- 09/09/20 Guggenheim
- Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
- 09/08/20 William Blair
- William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
- 09/08/20 Jefferies
- Albireo Pharma price target raised to $79 from $50 at Jefferies
- 11/11/20 Oppenheimer
- Amgen price target raised to $280 from $275 at Oppenheimer
- 11/11/20 HSBC
- AstraZeneca upgraded to Hold from Reduce at HSBC
- 11/11/20 HSBC
- AstraZeneca upgraded to Hold from Reduce at HSBC
- 10/23/20 Stifel
- FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
- 11/10/20 Bernstein
- Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
- 11/10/20 Bernstein
- Bristol-Myers initiated with a Market Perform at Bernstein
- 11/06/20 Gabelli
- Bristol-Myers downgraded to Hold from Buy at Gabelli
- 11/05/20 BofA
- BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
- 11/06/20 Raymond James
- CymaBay price target raised to $12 at Raymond James after Q3 report
- 09/25/20 Piper Sandler
- CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
- 09/09/20 B. Riley Securities
- CymaBay price target raised to $13 from $9 at B. Riley FBR
- 08/27/20 Piper Sandler
- Piper Sandler 'astonished' by seladelpar's long-term benefits
- 11/03/20 Chardan
- Durect Covid trial update increased interest in program, says Chardan
- 10/30/20
- Fly Intel: Top five analyst initiations
- 10/30/20 Chardan
- Durect initiated with a Buy at Chardan
- 10/20/20 Cantor Fitzgerald
- Durect assumed with an Overweight at Cantor Fitzgerald
- 11/05/20 Jefferies
- Eisai upgraded to Buy from Hold at Jefferies
- 09/08/20 Jefferies
- Eisai downgraded to Hold from Buy at Jefferies
- 10/26/20 Piper Sandler
- Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
- 09/22/20 Morgan Stanley
- Exelixis price target raised to $29 from $23 at Morgan Stanley
- 09/21/20 Piper Sandler
- Exelixis price target raised to $33 from $30 at Piper Sandler
- 06/30/20 Piper Sandler
- Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
- 11/13/20 Morgan Stanley
- GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
- 11/02/20 Liberum
- GlaxoSmithKline upgraded to Buy from Hold at Liberum
- 10/30/20 Barclays
- GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
- 10/27/20 Truist
- AnaptysBio price target raised to $27 from $20 at Truist
- 10/13/20 Roth Capital
- Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
- 08/17/20 H.C. Wainwright
- Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
- 08/05/20
- Fly Intel: Top five analyst initiations
- 08/05/20 Roth Capital
- Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals - 11/06/20 Goldman Sachs
- Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
- 11/06/20 Piper Sandler
- Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
- 11/06/20 H.C. Wainwright
- Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
- 11/05/20 Piper Sandler
- Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
- 08/06/20 Citi
- Mallinckrodt price target lowered to $1 from $2 at Citi
- 08/05/20 BMO Capital
- Mallinckrodt price target lowered to $2 from $4 at BMO Capital
- 08/04/20 Piper Sandler
- Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
- 07/14/20 BMO Capital
- Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
- 11/10/20 Bernstein
- Bernstein bullish on Merck, initiates with an Outperform
- 11/10/20 Bernstein
- Merck initiated with an Outperform at Bernstein
- 11/02/20 Raymond James
- Jounce Therapeutics downgraded to Market Perform at Raymond James
- 10/23/20
- Fly Intel: Pre-market Movers
- 11/10/20 Truist
- Match Group price target raised to $150 from $125 at Truist
- 11/10/20 Deutsche Bank
- Match Group price target raised to $160 from $150 at Deutsche Bank
- 11/09/20 Citi
- Match Group price target raised to $160 from $135 at Citi
- 09/24/20 Jefferies
- Match Group positioned to take advantage of pent up demand, says Jefferies
- 10/30/20 Mizuho
- Novocure price target raised to $150 from $84 at Mizuho
- 10/29/20 Piper Sandler
- Novocure price target raised to $140 from $125 at Piper Sandler
- 10/05/20 Piper Sandler
- Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
- 09/23/20
- Fly Intel: Top five analyst initiations
- 11/11/20 Truist
- Opthea initiated with a Buy at Truist
- 10/16/20 UBS
- Roche price target lowered to CHF 370 from CHF 390 at UBS
- 10/06/20 Goldman Sachs
- Goldman reiterates $34 target on Kiniksa after 'impressive' data
- 09/29/20 Berenberg
- Roche initiated with a Hold at Berenberg
- 10/27/20
- Oncolytics announces new GI cancer study using
- 10/15/20
- Roche confirms outlook for 2020 based on assessment of COVID-19
- 10/15/20
- Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year
- 09/11/20
- Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS
- 10/29/20
- Novocure reports Q3 EPS 9c, consensus 3c
- 07/30/20
- Novocure reports Q2 EPS 2c, consensus 0c
- 11/04/20
- Match Group sees Q4 revenue $640M-$650M, consensus $622.73M
- 11/04/20
- Match Group report Q3 EPS 45c, consensus 44c
- 11/04/20
- Notable companies reporting after market close
- 08/10/20
- IAC reports Q2 EPS ($1.13) vs. 16c a year ago
- 10/27/20
- Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78
- 10/27/20
- Merck reports Q3 adjusted EPS $1.74, consensus $1.43
- 10/26/20
- Notable companies reporting before tomorrow's open
- 08/04/20
- Mallinckrodt reports Q2 adj. EPS $1.89, consensus $1.34
MDGL Madrigal Pharmaceuticals - 11/05/20
- Madrigal Pharmaceuticals reports Q3 EPS ($3.75), consensus ($3.30)
- 08/06/20
- Madrigal Pharmaceuticals reports Q2 EPS ($3.18), consensus ($2.45)
- 10/28/20
- GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range
- 10/28/20
- GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago
- 10/08/20
- GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5%
- 07/29/20
- GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER
- 11/05/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $922M
- 11/05/20
- Exelixis reports Q3 adjusted EPS 4c, consensus 1c
- 08/06/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M
- 08/06/20
- Exelixis reports Q2 EPS 25c, consensus 12c
- 11/02/20
- Durect reports Q3 EPS (5c), consensus (4c)
- 08/03/20
- Durect reports Q2 EPS 7c, consensus 0c
- 11/05/20
- CymaBay reports Q3 EPS (17c), consensus (17c)
- 08/10/20
- CymaBay reports Q2 EPS (16c), consensus (24c)
- 11/05/20
- Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39
- 11/05/20
- Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25
- 11/05/20
- Bristol-Myers reports Q3 EPS $1.63, consensus $1.49
- 11/04/20
- Notable companies reporting before tomorrow's open
- 11/05/20
- AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage
- 11/05/20
- AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year
- 07/30/20
- AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS
- 07/30/20
- AstraZeneca reports Q2 core EPS 96c, up 31% at CER
- 11/05/20
- Albireo Pharma reports Q3 EPS ($1.96), consensus ($1.51)
- 08/06/20
- Albireo Pharma reports Q2 EPS ($1.38), consensus ($1.69)
|
Conference/Events
|
AASLD 2020: The Virtual… AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link ShowHide Related Items >><< - 11/13/20
- Halozyme: CHMP recommends EU approval of Roche's Phesgo
- 10/29/20
- Roche receives FDA approval for cobas EGFR Mutation Test v2
- 10/22/20
- Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527
- 10/21/20
- PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA
- 11/11/20
- Novocure receives CE Mark for NovoTTF-100L system
- 10/29/20
- Novocure forms alliance with NYU Grossman School of Medicine
- 08/13/20
- Novocure announces Wilco Groenhuysen as COO, other leadership promotions
- 07/22/20
- Novocure enrolls first patient in EF-33 Phase 2 pilot trial
- 11/04/20
- Match Group says future remains 'challenging to predict'
- 09/28/20
- Match Group appoints Tracey Breeden as Head of Safety and Social Advocacy
- 09/03/20
- Match Group says DOJ closes investigation
- 08/17/20
- Soros boosts stakes in Alphabet, T-Mobile, takes position in Alibaba
- 11/13/20
- FDA approves Merck's Keytruda in combination with chemo in TNBC
- 11/13/20
- Surface announces SRF617, SRF388 to advance to combination, expansion stages
- 11/11/20
- Xoma earns $1M milestone payment from 2018 royalty purchase agreement
- 11/11/20
- Moderna shares interim data from mRNA-4157 with Keytruda cohort at SITC
- 11/10/20
- Mallinckrodt initiates NOTICE study for use of INOmax gas in COVID-19 patients
- 10/21/20
- DOJ announces settlement agreement of over $8B with opioid maker Purdue Pharma
- 10/12/20
- Mallinckrodt voluntarily initiates Chapter 11 proceedings in bankruptcy court
- 10/12/20
- Mallinckrodt voluntarily initiates Chapter 11 proceedings
MDGL Madrigal Pharmaceuticals - 11/13/20
- Madrigal discloses data from MAESTRO-NAFLD trial ahead of AASLD presentation
- 10/01/20
- Madrigal announces acceptance of three abstracts for The Liver Meeting
- 09/03/20
- Madrigal exceeds target enrollment in Phase 3 MAESTRO NAFLD-1 trial
- 06/29/20
- Intercept plunges, drags down some NASH peers after CRL from FDA
- 11/10/20
- Inventiva announces conclusions from phase II meeting with FDA
- 11/06/20
- Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed
- 11/02/20
- Inventiva announces publication on role of PPARs in NASH treatment
- 10/19/20
- Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil
- 11/09/20
- GSK's ViiV says injectable cabotegravir superior to oral SOC for HIV prevention
- 11/02/20
- Horizon Therapeutics names Karin Rosen, M.D., Ph.D. as Chief Scientific Officer
- 10/28/20
- Sanofi, GSK to support COVAX with 200M doses of COVID-19 vaccine
- 10/26/20
- AnaptysBio, GlaxoSmithKline amend strategic immuno-oncology collaboration
- 10/27/20
- Exelixis announces Takeda, Ono submit application for Cabometyx in Japan
- 10/26/20
- Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo
- 10/19/20
- Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo
- 10/09/20
- Exelixis, Aurigene disclose new AUR102 data at ENA Symposium
- 11/10/20
- Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint
- 11/09/20
- Eisai presents latest BAN2401 data at CTAD
- 11/06/20
- Eisai down 19% as FDA panel votes on Alzheimer's drug candidate
- 10/30/20
- Biogen announces EMA acceptance of MAA for aducanumab
- 11/13/20
- Durect reports new safety data and efficacy signals from Phase 1b NASH trial
- 11/02/20
- Durect names Dr. Norman Sussman as Chief Medical Officer
- 10/05/20
- Durect to present results from 4-week Phase 1b clinical study of DUR-928
- 09/23/20
- Durect doses first patient in Phase 2 DUR-928 study of COVID-19 patients
- 11/05/20
- CymaBay announces study to evaluate potential of GPR119 agonists
- 08/27/20
- CymaBay presents final results from 52-week Phase 2 study in PBC
- 08/20/20
- CymaBay announces presentations during Digital International Liver Conference
- 08/03/20
- CymaBay announces topline results from ENHANCE for seladelpar
- 10/06/20
- IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat
- 08/31/20
- Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study
- 08/25/20
- Can-Fite BioPharma granted patent from EPO for Namodenoson
- 07/27/20
- Can-Fite BioPharma submits IND application for Phase 2 Piclidenoson study to FDA
- 11/12/20
- Bristol-Myers presents outcomes in 'hard to treat' blood cancers at ASH
- 11/09/20
- Stryker appoints Giovanni Caforio to board of directors
- 11/09/20
- Kitov expands planned Phase 1/2 clinical trial of CM24
- 11/09/20
- Bristol-Myers: Phase 2 study evaluating deucravacitinib met primary endpoint
- 11/13/20
- AstraZeneca announces data from U.S. hospitalized heart failure registry
- 11/13/20
- Ionis, AstraZeneca report efficacy and safety results of antisense medicine
- 11/12/20
- AstraZeneca says Phase 2 Calquence COVID-19 trials didn't meet primary endpoint
- 11/10/20
- AstraZeneca, Amgen study for severe asthma meets primary endpoint
- 11/13/20
- Albireo Pharma unveils novel bile acid modulators for adult liver diseases
- 11/13/20
- Albireo Pharma announces PEDFIC 1 meets primary, secondary endpoints
- 09/08/20
- Albireo Pharma jumps 64% after PEDFIC 1 Phase 3 trial met endpoints
- 09/08/20
- Albireo Pharma: PEDFIC 1 Phase 3 trial met two primary endpoints
- 09/10/20 Cowen
- Albireo Pharma price target raised to $65 from $39 at Cowen
- 09/09/20 Guggenheim
- Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
- 09/08/20 William Blair
- William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
- 09/08/20 Jefferies
- Albireo Pharma price target raised to $79 from $50 at Jefferies
- 11/11/20 Oppenheimer
- Amgen price target raised to $280 from $275 at Oppenheimer
- 11/11/20 HSBC
- AstraZeneca upgraded to Hold from Reduce at HSBC
- 11/11/20 HSBC
- AstraZeneca upgraded to Hold from Reduce at HSBC
- 10/23/20 Stifel
- FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
- 11/10/20 Bernstein
- Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
- 11/10/20 Bernstein
- Bristol-Myers initiated with a Market Perform at Bernstein
- 11/06/20 Gabelli
- Bristol-Myers downgraded to Hold from Buy at Gabelli
- 11/05/20 BofA
- BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
- 11/06/20 Raymond James
- CymaBay price target raised to $12 at Raymond James after Q3 report
- 09/25/20 Piper Sandler
- CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
- 09/09/20 B. Riley Securities
- CymaBay price target raised to $13 from $9 at B. Riley FBR
- 08/27/20 Piper Sandler
- Piper Sandler 'astonished' by seladelpar's long-term benefits
- 11/03/20 Chardan
- Durect Covid trial update increased interest in program, says Chardan
- 10/30/20
- Fly Intel: Top five analyst initiations
- 10/30/20 Chardan
- Durect initiated with a Buy at Chardan
- 10/20/20 Cantor Fitzgerald
- Durect assumed with an Overweight at Cantor Fitzgerald
- 11/05/20 Jefferies
- Eisai upgraded to Buy from Hold at Jefferies
- 09/08/20 Jefferies
- Eisai downgraded to Hold from Buy at Jefferies
- 10/26/20 Piper Sandler
- Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
- 09/22/20 Morgan Stanley
- Exelixis price target raised to $29 from $23 at Morgan Stanley
- 09/21/20 Piper Sandler
- Exelixis price target raised to $33 from $30 at Piper Sandler
- 06/30/20 Piper Sandler
- Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
- 11/13/20 Morgan Stanley
- GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
- 11/02/20 Liberum
- GlaxoSmithKline upgraded to Buy from Hold at Liberum
- 10/30/20 Barclays
- GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
- 10/27/20 Truist
- AnaptysBio price target raised to $27 from $20 at Truist
- 10/13/20 Roth Capital
- Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
- 08/17/20 H.C. Wainwright
- Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
- 08/05/20
- Fly Intel: Top five analyst initiations
- 08/05/20 Roth Capital
- Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals - 11/06/20 Goldman Sachs
- Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
- 11/06/20 Piper Sandler
- Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
- 11/06/20 H.C. Wainwright
- Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
- 11/05/20 Piper Sandler
- Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
- 08/06/20 Citi
- Mallinckrodt price target lowered to $1 from $2 at Citi
- 08/05/20 BMO Capital
- Mallinckrodt price target lowered to $2 from $4 at BMO Capital
- 08/04/20 Piper Sandler
- Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
- 07/14/20 BMO Capital
- Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
- 11/10/20 Bernstein
- Bernstein bullish on Merck, initiates with an Outperform
- 11/10/20 Bernstein
- Merck initiated with an Outperform at Bernstein
- 11/02/20 Raymond James
- Jounce Therapeutics downgraded to Market Perform at Raymond James
- 10/23/20
- Fly Intel: Pre-market Movers
- 11/10/20 Truist
- Match Group price target raised to $150 from $125 at Truist
- 11/10/20 Deutsche Bank
- Match Group price target raised to $160 from $150 at Deutsche Bank
- 11/09/20 Citi
- Match Group price target raised to $160 from $135 at Citi
- 09/24/20 Jefferies
- Match Group positioned to take advantage of pent up demand, says Jefferies
- 10/30/20 Mizuho
- Novocure price target raised to $150 from $84 at Mizuho
- 10/29/20 Piper Sandler
- Novocure price target raised to $140 from $125 at Piper Sandler
- 10/05/20 Piper Sandler
- Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
- 09/23/20
- Fly Intel: Top five analyst initiations
- 11/11/20 Truist
- Opthea initiated with a Buy at Truist
- 10/16/20 UBS
- Roche price target lowered to CHF 370 from CHF 390 at UBS
- 10/06/20 Goldman Sachs
- Goldman reiterates $34 target on Kiniksa after 'impressive' data
- 09/29/20 Berenberg
- Roche initiated with a Hold at Berenberg
- 10/27/20
- Oncolytics announces new GI cancer study using
- 10/15/20
- Roche confirms outlook for 2020 based on assessment of COVID-19
- 10/15/20
- Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year
- 09/11/20
- Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS
- 10/29/20
- Novocure reports Q3 EPS 9c, consensus 3c
- 07/30/20
- Novocure reports Q2 EPS 2c, consensus 0c
- 11/04/20
- Match Group sees Q4 revenue $640M-$650M, consensus $622.73M
- 11/04/20
- Match Group report Q3 EPS 45c, consensus 44c
- 11/04/20
- Notable companies reporting after market close
- 08/10/20
- IAC reports Q2 EPS ($1.13) vs. 16c a year ago
- 10/27/20
- Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78
- 10/27/20
- Merck reports Q3 adjusted EPS $1.74, consensus $1.43
- 10/26/20
- Notable companies reporting before tomorrow's open
- 08/04/20
- Mallinckrodt reports Q2 adj. EPS $1.89, consensus $1.34
MDGL Madrigal Pharmaceuticals - 11/05/20
- Madrigal Pharmaceuticals reports Q3 EPS ($3.75), consensus ($3.30)
- 08/06/20
- Madrigal Pharmaceuticals reports Q2 EPS ($3.18), consensus ($2.45)
- 10/28/20
- GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range
- 10/28/20
- GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago
- 10/08/20
- GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5%
- 07/29/20
- GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER
- 11/05/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $922M
- 11/05/20
- Exelixis reports Q3 adjusted EPS 4c, consensus 1c
- 08/06/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M
- 08/06/20
- Exelixis reports Q2 EPS 25c, consensus 12c
- 11/02/20
- Durect reports Q3 EPS (5c), consensus (4c)
- 08/03/20
- Durect reports Q2 EPS 7c, consensus 0c
- 11/05/20
- CymaBay reports Q3 EPS (17c), consensus (17c)
- 08/10/20
- CymaBay reports Q2 EPS (16c), consensus (24c)
- 11/05/20
- Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39
- 11/05/20
- Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25
- 11/05/20
- Bristol-Myers reports Q3 EPS $1.63, consensus $1.49
- 11/04/20
- Notable companies reporting before tomorrow's open
- 11/05/20
- AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage
- 11/05/20
- AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year
- 07/30/20
- AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS
- 07/30/20
- AstraZeneca reports Q2 core EPS 96c, up 31% at CER
- 11/05/20
- Albireo Pharma reports Q3 EPS ($1.96), consensus ($1.51)
- 08/06/20
- Albireo Pharma reports Q2 EPS ($1.38), consensus ($1.69)
|
Conference/Events
|
AASLD 2020: The Virtual… AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link ShowHide Related Items >><< - 11/13/20
- Halozyme: CHMP recommends EU approval of Roche's Phesgo
- 10/29/20
- Roche receives FDA approval for cobas EGFR Mutation Test v2
- 10/22/20
- Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527
- 10/21/20
- PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA
- 11/11/20
- Novocure receives CE Mark for NovoTTF-100L system
- 10/29/20
- Novocure forms alliance with NYU Grossman School of Medicine
- 08/13/20
- Novocure announces Wilco Groenhuysen as COO, other leadership promotions
- 07/22/20
- Novocure enrolls first patient in EF-33 Phase 2 pilot trial
- 11/04/20
- Match Group says future remains 'challenging to predict'
- 09/28/20
- Match Group appoints Tracey Breeden as Head of Safety and Social Advocacy
- 09/03/20
- Match Group says DOJ closes investigation
- 08/17/20
- Soros boosts stakes in Alphabet, T-Mobile, takes position in Alibaba
- 11/13/20
- FDA approves Merck's Keytruda in combination with chemo in TNBC
- 11/13/20
- Surface announces SRF617, SRF388 to advance to combination, expansion stages
- 11/11/20
- Xoma earns $1M milestone payment from 2018 royalty purchase agreement
- 11/11/20
- Moderna shares interim data from mRNA-4157 with Keytruda cohort at SITC
- 11/10/20
- Mallinckrodt initiates NOTICE study for use of INOmax gas in COVID-19 patients
- 10/21/20
- DOJ announces settlement agreement of over $8B with opioid maker Purdue Pharma
- 10/12/20
- Mallinckrodt voluntarily initiates Chapter 11 proceedings in bankruptcy court
- 10/12/20
- Mallinckrodt voluntarily initiates Chapter 11 proceedings
MDGL Madrigal Pharmaceuticals - 11/13/20
- Madrigal discloses data from MAESTRO-NAFLD trial ahead of AASLD presentation
- 10/01/20
- Madrigal announces acceptance of three abstracts for The Liver Meeting
- 09/03/20
- Madrigal exceeds target enrollment in Phase 3 MAESTRO NAFLD-1 trial
- 06/29/20
- Intercept plunges, drags down some NASH peers after CRL from FDA
- 11/10/20
- Inventiva announces conclusions from phase II meeting with FDA
- 11/06/20
- Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed
- 11/02/20
- Inventiva announces publication on role of PPARs in NASH treatment
- 10/19/20
- Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil
- 11/09/20
- GSK's ViiV says injectable cabotegravir superior to oral SOC for HIV prevention
- 11/02/20
- Horizon Therapeutics names Karin Rosen, M.D., Ph.D. as Chief Scientific Officer
- 10/28/20
- Sanofi, GSK to support COVAX with 200M doses of COVID-19 vaccine
- 10/26/20
- AnaptysBio, GlaxoSmithKline amend strategic immuno-oncology collaboration
- 10/27/20
- Exelixis announces Takeda, Ono submit application for Cabometyx in Japan
- 10/26/20
- Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo
- 10/19/20
- Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo
- 10/09/20
- Exelixis, Aurigene disclose new AUR102 data at ENA Symposium
- 11/10/20
- Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint
- 11/09/20
- Eisai presents latest BAN2401 data at CTAD
- 11/06/20
- Eisai down 19% as FDA panel votes on Alzheimer's drug candidate
- 10/30/20
- Biogen announces EMA acceptance of MAA for aducanumab
- 11/13/20
- Durect reports new safety data and efficacy signals from Phase 1b NASH trial
- 11/02/20
- Durect names Dr. Norman Sussman as Chief Medical Officer
- 10/05/20
- Durect to present results from 4-week Phase 1b clinical study of DUR-928
- 09/23/20
- Durect doses first patient in Phase 2 DUR-928 study of COVID-19 patients
- 11/05/20
- CymaBay announces study to evaluate potential of GPR119 agonists
- 08/27/20
- CymaBay presents final results from 52-week Phase 2 study in PBC
- 08/20/20
- CymaBay announces presentations during Digital International Liver Conference
- 08/03/20
- CymaBay announces topline results from ENHANCE for seladelpar
- 10/06/20
- IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat
- 08/31/20
- Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study
- 08/25/20
- Can-Fite BioPharma granted patent from EPO for Namodenoson
- 07/27/20
- Can-Fite BioPharma submits IND application for Phase 2 Piclidenoson study to FDA
- 11/12/20
- Bristol-Myers presents outcomes in 'hard to treat' blood cancers at ASH
- 11/09/20
- Stryker appoints Giovanni Caforio to board of directors
- 11/09/20
- Kitov expands planned Phase 1/2 clinical trial of CM24
- 11/09/20
- Bristol-Myers: Phase 2 study evaluating deucravacitinib met primary endpoint
- 11/13/20
- AstraZeneca announces data from U.S. hospitalized heart failure registry
- 11/13/20
- Ionis, AstraZeneca report efficacy and safety results of antisense medicine
- 11/12/20
- AstraZeneca says Phase 2 Calquence COVID-19 trials didn't meet primary endpoint
- 11/10/20
- AstraZeneca, Amgen study for severe asthma meets primary endpoint
- 11/13/20
- Albireo Pharma unveils novel bile acid modulators for adult liver diseases
- 11/13/20
- Albireo Pharma announces PEDFIC 1 meets primary, secondary endpoints
- 09/08/20
- Albireo Pharma jumps 64% after PEDFIC 1 Phase 3 trial met endpoints
- 09/08/20
- Albireo Pharma: PEDFIC 1 Phase 3 trial met two primary endpoints
- 09/10/20 Cowen
- Albireo Pharma price target raised to $65 from $39 at Cowen
- 09/09/20 Guggenheim
- Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
- 09/08/20 William Blair
- William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
- 09/08/20 Jefferies
- Albireo Pharma price target raised to $79 from $50 at Jefferies
- 11/11/20 Oppenheimer
- Amgen price target raised to $280 from $275 at Oppenheimer
- 11/11/20 HSBC
- AstraZeneca upgraded to Hold from Reduce at HSBC
- 11/11/20 HSBC
- AstraZeneca upgraded to Hold from Reduce at HSBC
- 10/23/20 Stifel
- FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
- 11/10/20 Bernstein
- Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
- 11/10/20 Bernstein
- Bristol-Myers initiated with a Market Perform at Bernstein
- 11/06/20 Gabelli
- Bristol-Myers downgraded to Hold from Buy at Gabelli
- 11/05/20 BofA
- BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
- 11/06/20 Raymond James
- CymaBay price target raised to $12 at Raymond James after Q3 report
- 09/25/20 Piper Sandler
- CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
- 09/09/20 B. Riley Securities
- CymaBay price target raised to $13 from $9 at B. Riley FBR
- 08/27/20 Piper Sandler
- Piper Sandler 'astonished' by seladelpar's long-term benefits
- 11/03/20 Chardan
- Durect Covid trial update increased interest in program, says Chardan
- 10/30/20
- Fly Intel: Top five analyst initiations
- 10/30/20 Chardan
- Durect initiated with a Buy at Chardan
- 10/20/20 Cantor Fitzgerald
- Durect assumed with an Overweight at Cantor Fitzgerald
- 11/05/20 Jefferies
- Eisai upgraded to Buy from Hold at Jefferies
- 09/08/20 Jefferies
- Eisai downgraded to Hold from Buy at Jefferies
- 10/26/20 Piper Sandler
- Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
- 09/22/20 Morgan Stanley
- Exelixis price target raised to $29 from $23 at Morgan Stanley
- 09/21/20 Piper Sandler
- Exelixis price target raised to $33 from $30 at Piper Sandler
- 06/30/20 Piper Sandler
- Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
- 11/13/20 Morgan Stanley
- GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
- 11/02/20 Liberum
- GlaxoSmithKline upgraded to Buy from Hold at Liberum
- 10/30/20 Barclays
- GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
- 10/27/20 Truist
- AnaptysBio price target raised to $27 from $20 at Truist
- 10/13/20 Roth Capital
- Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
- 08/17/20 H.C. Wainwright
- Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
- 08/05/20
- Fly Intel: Top five analyst initiations
- 08/05/20 Roth Capital
- Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals - 11/06/20 Goldman Sachs
- Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
- 11/06/20 Piper Sandler
- Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
- 11/06/20 H.C. Wainwright
- Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
- 11/05/20 Piper Sandler
- Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
- 08/06/20 Citi
- Mallinckrodt price target lowered to $1 from $2 at Citi
- 08/05/20 BMO Capital
- Mallinckrodt price target lowered to $2 from $4 at BMO Capital
- 08/04/20 Piper Sandler
- Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
- 07/14/20 BMO Capital
- Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
- 11/10/20 Bernstein
- Bernstein bullish on Merck, initiates with an Outperform
- 11/10/20 Bernstein
- Merck initiated with an Outperform at Bernstein
- 11/02/20 Raymond James
- Jounce Therapeutics downgraded to Market Perform at Raymond James
- 10/23/20
- Fly Intel: Pre-market Movers
- 11/10/20 Truist
- Match Group price target raised to $150 from $125 at Truist
- 11/10/20 Deutsche Bank
- Match Group price target raised to $160 from $150 at Deutsche Bank
- 11/09/20 Citi
- Match Group price target raised to $160 from $135 at Citi
- 09/24/20 Jefferies
- Match Group positioned to take advantage of pent up demand, says Jefferies
- 10/30/20 Mizuho
- Novocure price target raised to $150 from $84 at Mizuho
- 10/29/20 Piper Sandler
- Novocure price target raised to $140 from $125 at Piper Sandler
- 10/05/20 Piper Sandler
- Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
- 09/23/20
- Fly Intel: Top five analyst initiations
- 11/11/20 Truist
- Opthea initiated with a Buy at Truist
- 10/16/20 UBS
- Roche price target lowered to CHF 370 from CHF 390 at UBS
- 10/06/20 Goldman Sachs
- Goldman reiterates $34 target on Kiniksa after 'impressive' data
- 09/29/20 Berenberg
- Roche initiated with a Hold at Berenberg
- 10/27/20
- Oncolytics announces new GI cancer study using
- 10/15/20
- Roche confirms outlook for 2020 based on assessment of COVID-19
- 10/15/20
- Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year
- 09/11/20
- Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS
- 10/29/20
- Novocure reports Q3 EPS 9c, consensus 3c
- 07/30/20
- Novocure reports Q2 EPS 2c, consensus 0c
- 11/04/20
- Match Group sees Q4 revenue $640M-$650M, consensus $622.73M
- 11/04/20
- Match Group report Q3 EPS 45c, consensus 44c
- 11/04/20
- Notable companies reporting after market close
- 08/10/20
- IAC reports Q2 EPS ($1.13) vs. 16c a year ago
- 10/27/20
- Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78
- 10/27/20
- Merck reports Q3 adjusted EPS $1.74, consensus $1.43
- 10/26/20
- Notable companies reporting before tomorrow's open
- 08/04/20
- Mallinckrodt reports Q2 adj. EPS $1.89, consensus $1.34
MDGL Madrigal Pharmaceuticals - 11/05/20
- Madrigal Pharmaceuticals reports Q3 EPS ($3.75), consensus ($3.30)
- 08/06/20
- Madrigal Pharmaceuticals reports Q2 EPS ($3.18), consensus ($2.45)
- 10/28/20
- GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range
- 10/28/20
- GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago
- 10/08/20
- GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5%
- 07/29/20
- GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER
- 11/05/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $922M
- 11/05/20
- Exelixis reports Q3 adjusted EPS 4c, consensus 1c
- 08/06/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M
- 08/06/20
- Exelixis reports Q2 EPS 25c, consensus 12c
- 11/02/20
- Durect reports Q3 EPS (5c), consensus (4c)
- 08/03/20
- Durect reports Q2 EPS 7c, consensus 0c
- 11/05/20
- CymaBay reports Q3 EPS (17c), consensus (17c)
- 08/10/20
- CymaBay reports Q2 EPS (16c), consensus (24c)
- 11/05/20
- Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39
- 11/05/20
- Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25
- 11/05/20
- Bristol-Myers reports Q3 EPS $1.63, consensus $1.49
- 11/04/20
- Notable companies reporting before tomorrow's open
- 11/05/20
- AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage
- 11/05/20
- AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year
- 07/30/20
- AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS
- 07/30/20
- AstraZeneca reports Q2 core EPS 96c, up 31% at CER
- 11/05/20
- Albireo Pharma reports Q3 EPS ($1.96), consensus ($1.51)
- 08/06/20
- Albireo Pharma reports Q2 EPS ($1.38), consensus ($1.69)
|
Conference/Events
|
AASLD 2020: The Virtual… AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link ShowHide Related Items >><< - 10/29/20
- Roche receives FDA approval for cobas EGFR Mutation Test v2
- 10/22/20
- Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527
- 10/21/20
- PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA
- 10/20/20
- Prothena, Roche to advance prasinezumab into late-stage clinical development
- 11/11/20
- Novocure receives CE Mark for NovoTTF-100L system
- 10/29/20
- Novocure forms alliance with NYU Grossman School of Medicine
- 08/13/20
- Novocure announces Wilco Groenhuysen as COO, other leadership promotions
- 07/22/20
- Novocure enrolls first patient in EF-33 Phase 2 pilot trial
- 11/04/20
- Match Group says future remains 'challenging to predict'
- 09/28/20
- Match Group appoints Tracey Breeden as Head of Safety and Social Advocacy
- 09/03/20
- Match Group says DOJ closes investigation
- 08/17/20
- Soros boosts stakes in Alphabet, T-Mobile, takes position in Alibaba
- 11/13/20
- Surface announces SRF617, SRF388 to advance to combination, expansion stages
- 11/11/20
- Xoma earns $1M milestone payment from 2018 royalty purchase agreement
- 11/11/20
- Moderna shares interim data from mRNA-4157 with Keytruda cohort at SITC
- 11/10/20
- Agenus: Milestone payment from Merck triggered as MK-4830 enters Phase 2
- 11/10/20
- Mallinckrodt initiates NOTICE study for use of INOmax gas in COVID-19 patients
- 10/21/20
- DOJ announces settlement agreement of over $8B with opioid maker Purdue Pharma
- 10/12/20
- Mallinckrodt voluntarily initiates Chapter 11 proceedings in bankruptcy court
- 10/12/20
- Mallinckrodt voluntarily initiates Chapter 11 proceedings
MDGL Madrigal Pharmaceuticals - 10/01/20
- Madrigal announces acceptance of three abstracts for The Liver Meeting
- 09/03/20
- Madrigal exceeds target enrollment in Phase 3 MAESTRO NAFLD-1 trial
- 06/29/20
- Intercept plunges, drags down some NASH peers after CRL from FDA
- 11/10/20
- Inventiva announces conclusions from phase II meeting with FDA
- 11/06/20
- Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed
- 11/02/20
- Inventiva announces publication on role of PPARs in NASH treatment
- 10/19/20
- Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil
- $37.75 /
-0.4281 (-1.12%) - 11/09/20
- GSK's ViiV says injectable cabotegravir superior to oral SOC for HIV prevention
- 11/02/20
- Horizon Therapeutics names Karin Rosen, M.D., Ph.D. as Chief Scientific Officer
- 10/28/20
- Sanofi, GSK to support COVAX with 200M doses of COVID-19 vaccine
- 10/26/20
- AnaptysBio, GlaxoSmithKline amend strategic immuno-oncology collaboration
- 10/27/20
- Exelixis announces Takeda, Ono submit application for Cabometyx in Japan
- 10/26/20
- Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo
- 10/19/20
- Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo
- 10/09/20
- Exelixis, Aurigene disclose new AUR102 data at ENA Symposium
- 11/10/20
- Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint
- 11/09/20
- Eisai presents latest BAN2401 data at CTAD
- 11/06/20
- Eisai down 19% as FDA panel votes on Alzheimer's drug candidate
- 10/30/20
- Biogen announces EMA acceptance of MAA for aducanumab
- 11/02/20
- Durect names Dr. Norman Sussman as Chief Medical Officer
- 10/05/20
- Durect to present results from 4-week Phase 1b clinical study of DUR-928
- 09/23/20
- Durect doses first patient in Phase 2 DUR-928 study of COVID-19 patients
- 09/22/20
- Durect expects 300 person alcoholic hepatitis study to begin in October
- 11/05/20
- CymaBay announces study to evaluate potential of GPR119 agonists
- 08/27/20
- CymaBay presents final results from 52-week Phase 2 study in PBC
- 08/20/20
- CymaBay announces presentations during Digital International Liver Conference
- 08/03/20
- CymaBay announces topline results from ENHANCE for seladelpar
- 10/06/20
- IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat
- 08/31/20
- Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study
- 08/25/20
- Can-Fite BioPharma granted patent from EPO for Namodenoson
- 07/27/20
- Can-Fite BioPharma submits IND application for Phase 2 Piclidenoson study to FDA
- 11/12/20
- Bristol-Myers presents outcomes in 'hard to treat' blood cancers at ASH
- 11/09/20
- Stryker appoints Giovanni Caforio to board of directors
- 11/09/20
- Kitov expands planned Phase 1/2 clinical trial of CM24
- 11/09/20
- Bristol-Myers: Phase 2 study evaluating deucravacitinib met primary endpoint
- 11/13/20
- Ionis, AstraZeneca report efficacy and safety results of antisense medicine
- 11/12/20
- AstraZeneca says Phase 2 Calquence COVID-19 trials didn't meet primary endpoint
- 11/10/20
- AstraZeneca, Amgen study for severe asthma meets primary endpoint
- 11/10/20
- Amgen, AstraZeneca announce NAVIGATOR trial meets primary endpoint
- 11/13/20
- Albireo Pharma unveils novel bile acid modulators for adult liver diseases
- 11/13/20
- Albireo Pharma announces PEDFIC 1 meets primary, secondary endpoints
- 09/08/20
- Albireo Pharma jumps 64% after PEDFIC 1 Phase 3 trial met endpoints
- 09/08/20
- Albireo Pharma: PEDFIC 1 Phase 3 trial met two primary endpoints
- 09/10/20 Cowen
- Albireo Pharma price target raised to $65 from $39 at Cowen
- 09/09/20 Guggenheim
- Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
- 09/08/20 William Blair
- William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
- 09/08/20 Jefferies
- Albireo Pharma price target raised to $79 from $50 at Jefferies
- 11/11/20 Oppenheimer
- Amgen price target raised to $280 from $275 at Oppenheimer
- 11/11/20 HSBC
- AstraZeneca upgraded to Hold from Reduce at HSBC
- 11/11/20 HSBC
- AstraZeneca upgraded to Hold from Reduce at HSBC
- 10/23/20 Stifel
- FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
- 11/10/20 Bernstein
- Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
- 11/10/20 Bernstein
- Bristol-Myers initiated with a Market Perform at Bernstein
- 11/06/20 Gabelli
- Bristol-Myers downgraded to Hold from Buy at Gabelli
- 11/05/20 BofA
- BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
- 11/06/20 Raymond James
- CymaBay price target raised to $12 at Raymond James after Q3 report
- 09/25/20 Piper Sandler
- CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
- 09/09/20 B. Riley Securities
- CymaBay price target raised to $13 from $9 at B. Riley FBR
- 08/27/20 Piper Sandler
- Piper Sandler 'astonished' by seladelpar's long-term benefits
- 11/03/20 Chardan
- Durect Covid trial update increased interest in program, says Chardan
- 10/30/20
- Fly Intel: Top five analyst initiations
- 10/30/20 Chardan
- Durect initiated with a Buy at Chardan
- 10/20/20 Cantor Fitzgerald
- Durect assumed with an Overweight at Cantor Fitzgerald
- 11/05/20 Jefferies
- Eisai upgraded to Buy from Hold at Jefferies
- 09/08/20 Jefferies
- Eisai downgraded to Hold from Buy at Jefferies
- 10/26/20 Piper Sandler
- Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
- 09/22/20 Morgan Stanley
- Exelixis price target raised to $29 from $23 at Morgan Stanley
- 09/21/20 Piper Sandler
- Exelixis price target raised to $33 from $30 at Piper Sandler
- 06/30/20 Piper Sandler
- Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
- $37.75 /
-0.4281 (-1.12%) - 11/13/20 Morgan Stanley
- GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
- 11/02/20 Liberum
- GlaxoSmithKline upgraded to Buy from Hold at Liberum
- 10/30/20 Barclays
- GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
- 10/27/20 Truist
- AnaptysBio price target raised to $27 from $20 at Truist
- 10/13/20 Roth Capital
- Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
- 08/17/20 H.C. Wainwright
- Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
- 08/05/20
- Fly Intel: Top five analyst initiations
- 08/05/20 Roth Capital
- Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals - 11/06/20 Goldman Sachs
- Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
- 11/06/20 Piper Sandler
- Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
- 11/06/20 H.C. Wainwright
- Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
- 11/05/20 Piper Sandler
- Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
- 08/06/20 Citi
- Mallinckrodt price target lowered to $1 from $2 at Citi
- 08/05/20 BMO Capital
- Mallinckrodt price target lowered to $2 from $4 at BMO Capital
- 08/04/20 Piper Sandler
- Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
- 07/14/20 BMO Capital
- Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
- 11/10/20 Bernstein
- Bernstein bullish on Merck, initiates with an Outperform
- 11/10/20 Bernstein
- Merck initiated with an Outperform at Bernstein
- 11/02/20 Raymond James
- Jounce Therapeutics downgraded to Market Perform at Raymond James
- 10/23/20
- Fly Intel: Pre-market Movers
- 11/10/20 Truist
- Match Group price target raised to $150 from $125 at Truist
- 11/10/20 Deutsche Bank
- Match Group price target raised to $160 from $150 at Deutsche Bank
- 11/09/20 Citi
- Match Group price target raised to $160 from $135 at Citi
- 09/24/20 Jefferies
- Match Group positioned to take advantage of pent up demand, says Jefferies
- 10/30/20 Mizuho
- Novocure price target raised to $150 from $84 at Mizuho
- 10/29/20 Piper Sandler
- Novocure price target raised to $140 from $125 at Piper Sandler
- 10/05/20 Piper Sandler
- Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
- 09/23/20
- Fly Intel: Top five analyst initiations
- 11/11/20 Truist
- Opthea initiated with a Buy at Truist
- 10/16/20 UBS
- Roche price target lowered to CHF 370 from CHF 390 at UBS
- 10/06/20 Goldman Sachs
- Goldman reiterates $34 target on Kiniksa after 'impressive' data
- 09/29/20 Berenberg
- Roche initiated with a Hold at Berenberg
- 10/27/20
- Oncolytics announces new GI cancer study using
- 10/15/20
- Roche confirms outlook for 2020 based on assessment of COVID-19
- 10/15/20
- Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year
- 09/11/20
- Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS
- 10/29/20
- Novocure reports Q3 EPS 9c, consensus 3c
- 07/30/20
- Novocure reports Q2 EPS 2c, consensus 0c
- 11/04/20
- Match Group sees Q4 revenue $640M-$650M, consensus $622.73M
- 11/04/20
- Match Group report Q3 EPS 45c, consensus 44c
- 11/04/20
- Notable companies reporting after market close
- 08/10/20
- IAC reports Q2 EPS ($1.13) vs. 16c a year ago
- 10/27/20
- Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78
- 10/27/20
- Merck reports Q3 adjusted EPS $1.74, consensus $1.43
- 10/26/20
- Notable companies reporting before tomorrow's open
- 08/04/20
- Mallinckrodt reports Q2 adj. EPS $1.89, consensus $1.34
MDGL Madrigal Pharmaceuticals - 11/05/20
- Madrigal Pharmaceuticals reports Q3 EPS ($3.75), consensus ($3.30)
- 08/06/20
- Madrigal Pharmaceuticals reports Q2 EPS ($3.18), consensus ($2.45)
- $37.75 /
-0.4281 (-1.12%) - 10/28/20
- GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range
- 10/28/20
- GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago
- 10/08/20
- GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5%
- 07/29/20
- GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER
- 11/05/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $922M
- 11/05/20
- Exelixis reports Q3 adjusted EPS 4c, consensus 1c
- 08/06/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M
- 08/06/20
- Exelixis reports Q2 EPS 25c, consensus 12c
- 11/02/20
- Durect reports Q3 EPS (5c), consensus (4c)
- 08/03/20
- Durect reports Q2 EPS 7c, consensus 0c
- 11/05/20
- CymaBay reports Q3 EPS (17c), consensus (17c)
- 08/10/20
- CymaBay reports Q2 EPS (16c), consensus (24c)
- 11/05/20
- Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39
- 11/05/20
- Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25
- 11/05/20
- Bristol-Myers reports Q3 EPS $1.63, consensus $1.49
- 11/04/20
- Notable companies reporting before tomorrow's open
- 11/05/20
- AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage
- 11/05/20
- AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year
- 07/30/20
- AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS
- 07/30/20
- AstraZeneca reports Q2 core EPS 96c, up 31% at CER
- 11/05/20
- Albireo Pharma reports Q3 EPS ($1.96), consensus ($1.51)
- 08/06/20
- Albireo Pharma reports Q2 EPS ($1.38), consensus ($1.69)
|